Skip to content

Phase I Trial of Anti-CD19 Universal CAR-T Therapy For Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase I Trial of Anti-CD19 Universal CAR-T Therapy For Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051028
Enrollment
Unknown
Registered
2021-09-10
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rr DLBCL

Interventions

DL1:Infusion of 100×10^6?CAR+ cell
DL2:Infusion of 300×10^6?CAR+ cell
DL3:Infusion of 600×10^6?CAR+ cell

Sponsors

Tangdu Hospital, Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 3 months; 4. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions): a) CR not achieved after 2 lines of standardized chemotherapy; b) and or relapse after CR. 5. Recent therapy ended (including radiation therapy, chemotherapy, monoclonal antibody or other related therapies) beyond 4 weeks; 6. No active infection; 7. Not participated other interventionary clinical trials in the past 3 months; 8. ECOG <= 2; 9. Patients or their legal guardians understand this trail and volunteer to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with New York Heart Associate (NYHA) Class III/IV cardiac insufficiency, LVEF < 50; 2. Sever lung dis-function history; 3. With other type of malignancy; 4. Sever infection which cannot be controlled; 5. With metabolic disorder (except for diabetes); 6. With autoimmune disease or genetic immunodeficiency; 7. Active hepatitis (HBV DNA or HCV RNA positive); 8. HIV infection; 9. Bio-product related allergy (including antibiotics); 10. With grade 34 acute GvHD history or patients with GvHD after stem cell transplantation; 11. CNS tumor cell evidence; 12. Women patients with pregnancy or in breast feeding period; 13. Other conditions or situations which principal investigator believes that would increase subjects risk or may interference the results.

Design outcomes

Primary

MeasureTime frame
Dose-limiting toxicity;complete remission, CR/CR with incomplete count recovery, CRi;Objective Response Rate, ORR;

Secondary

MeasureTime frame
overall survival, OS;progression-free survival, PFS;

Countries

China

Contacts

Public ContactLiu Li

Tangdu Hospital, Fourth Military Medical University

liuli1@medmail.com.cn+86 13488222789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026